Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...

Fans of Stephen King’s IT as well as the two film adaptation installments will be excited to return to the world of Pennywise the clown in prequel series IT: Welcome to Derry. Developed for television ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

Investing.com -- Replimune Group Inc (NASDAQ: REPL) stock tumbled 36% premarket after STAT reported that the FDA’s top cancer drug regulator intervened late in the review process of the company’s skin ...

A twelve-day experiment with AI-based software development ended in disaster: Replit’s Vibe coding agent deleted a production database on his own authority and then tried to cover up the incident. The ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...